| 引用本文: | 高鹏,刘银,黄凌斐,朱正怡,倪映华,杨巨飞,缪静.儿童奈玛特韦/利托那韦片临床使用情况及药物相互作用分析[J].中国现代应用药学,2023,40(22):3164-3168. |
| GAO Peng,LIU Yin,HUANG Lingfei,ZHU Zhengyi,NI Yinghua,YANG Jufei,MIAO Jing.Clinical Application and Drug Interaction Analysis of Nirmatrelvir/Ritonavir Tablets in Children[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(22):3164-3168. |
|
| 本文已被：浏览 2515次 下载 500次 |
码上扫一扫！ |
|
|
| 儿童奈玛特韦/利托那韦片临床使用情况及药物相互作用分析 |
|
高鹏1, 刘银1, 黄凌斐1, 朱正怡1, 倪映华1, 杨巨飞1, 缪静1,2
|
|
1.浙江大学医学院附属儿童医院药剂科, 国家儿童健康与疾病临床医学研究中心, 杭州 310052;2.浙江大学临床药学研究中心, 杭州 310058
|
|
| 摘要: |
| 目的 分析儿童奈玛特韦/利托那韦片的使用及治疗过程中药物相互作用情况，为临床合理用药提供参考。方法 收集2022年12月23日—2023年2月8日浙江大学医学院附属儿童医院所有使用奈玛特韦/利托那韦片的住院患儿病例资料，分析该药的使用情况，并对相关的联用药物进行分类，通过micromedex药物相互作用数据库分析该药的临床潜在相互作用药物情况并进行严重性分级。结果 共收集使用奈玛特韦/利托那韦片病例48例，中位年龄6.71岁，年龄范围87 d~17.75岁。使用科室集中在血液科、ICU、感染科、综合内科，合并基础疾病主要为肿瘤，用药后中位退热时间3 d。用药期间联用药物较多，共收集奈玛特韦/利托那韦片潜在相互作用药物15种，需关注与抗真菌药的潜在药物相互作用。结论 儿童使用奈玛特韦/利托那韦片较多的科室为血液科，合并基础疾病主要为肿瘤，用药期间联用潜在相互作用的药物时应当注意监测疗效和药物不良反应。 |
| 关键词: 奈玛特韦 利托那韦 儿科 药物相互作用 |
| DOI：10.13748/j.cnki.issn1007-7693.20232536 |
| 分类号:R969.3 |
| 基金项目:浙江省药学会医院药学专项科研资助项目(2022ZYY04) |
|
| Clinical Application and Drug Interaction Analysis of Nirmatrelvir/Ritonavir Tablets in Children |
|
GAO Peng1, LIU Yin1, HUANG Lingfei1, ZHU Zhengyi1, NI Yinghua1, YANG Jufei1, MIAO Jing1,2
|
|
1.Department of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China;2.Research Center for Clinical Pharmacy, Zhejiang University, Hangzhou 310058, China
|
| Abstract: |
| OBJECTIVE To analyze the drug-drug interaction during the use and treatment of nirmatrelvir/ritonavir tablets in children, and to provide reference for rational drug use in clinical practice. METHODS All hospitalized pediatric patients with using nirmatrelvir/ritonavir tablets from December 23, 2022 to February 8, 2023 in Children's Hospital, Zhejiang University School of Medicine were collected. The use of nirmatrelvir/ritonavir was analyzed, and the combination drugs were classified. The potential clinical drug-drug interactions of nirmatrelvir/ritonavir were analyzed through micromedex drug interaction database and the severity was graded. RESULTS A total of 48 patients using nirmatrelvir/ritonavir tablets were collected, with a median age of 6.71 years old(87 d-17.75 years old). The usage departments were mainly in the departments of hematology, ICU, infectious disease, and general internal medicine, and the main underlying disease being tumors. The median fever-reducing time after medication was 3 d. Many drugs were combined during medication period. A total of 15 potential drug-drug interaction drugs of nirmatrelvir/ritonavir tablets were collected, and potential drug interaction with antifungals should be considered. CONCLUSION The department with more usage of nirmatrelvir/ritonavir tablets in children is hematology, and the main underlying disease is tumors. When nirmatrelvir/ritonavir tablets are used in combination with potential drug-drug interaction drugs, attention should be paid to monitoring the efficacy and adverse reactions. |
| Key words: nirmatrelvir ritonavir pediatrics drug-drug interactions |
